Toxocariasis

Toxocariasis is a parasitic disease caused by infection with nematodes of the genus Toxocara, primarily Toxocara canis in dogs and Toxocara cati in cats. These ascarid roundworms reside in the small intestine of their definitive hosts, where they cause significant morbidity, particularly in young animals. The disease encompasses both intestinal infection in definitive hosts and visceral or ocular larva migrans in paratenic hosts (including humans). In veterinary medicine, toxocariasis is a major concern due to its high prevalence, zoonotic potential, and impact on puppy and kitten health. The lifecycle involves fecal-oral transmission, transplacental and transmammary routes in dogs, and transmammary and paratenic host ingestion in cats. Clinical manifestations range from subclinical infections to severe enteritis, malnutrition, and respiratory signs in neonates. The disease is globally distributed, with higher prevalence in tropical and subtropical regions and in areas with poor sanitation. Effective control requires strategic deworming, environmental hygiene, and public health education.

The primary causative agents are Toxocara canis (affecting canids) and Toxocara cati (affecting felids). Toxocara canis is a large, yellowish-white ascarid, with males measuring 4-6 cm and females 6-15 cm in length. Toxocara cati is slightly smaller, with males 3-6 cm and females 4-10 cm. The adult worms have three lips and cervical alae; T. cati has distinctive arrow-shaped cervical alae. The eggs are thick-shelled, subspherical, and measure approximately 75-90 μm for T. canis and 65-75 μm for T. cati. Infective eggs contain a second-stage larva (L2) after embryonation in the environment, which requires 2-6 weeks under optimal conditions (warm, moist, shaded soil). Transmission occurs via ingestion of embryonated eggs from contaminated soil, fomites, or grooming; ingestion of paratenic hosts (e.g., rodents, birds) containing hypobiotic L3 larvae; and, in dogs, transplacental (prenatal) and transmammary (lactogenic) transmission. In cats, transplacental transmission is rare, but transmammary transmission is significant. The lifecycle involves a hepatopulmonary tracheal migration in neonatal animals, while in older animals, larvae undergo somatic migration and become arrested in tissues, leading to hypobiosis. In paratenic hosts, larvae remain in the somatic tissues and can be reactivated during pregnancy in female definitive hosts.

Toxocariasis is a globally distributed zoonotic disease with a higher prevalence in tropical and subtropical regions, as well as in areas with poor sanitation and high stray animal populations. In dogs, prevalence rates vary widely: puppies are commonly infected, with studies reporting up to 100% prevalence in some populations, while adult dogs have lower prevalence (10-30%) due to age-related immunity. In cats, prevalence ranges from 10-50%, with higher rates in kittens and free-roaming cats. Breed predispositions are not well-defined, but environmental factors such as kennel conditions, overcrowding, and lack of routine deworming significantly increase risk. Age is a critical factor: puppies and kittens are most susceptible due to transplacental and transmammary transmission, and they shed large numbers of eggs. Sex predilection is not significant. Geographic distribution is influenced by climate; embryonation of eggs requires adequate warmth and humidity, so temperate and tropical regions have higher infection pressure. Seasonality is less pronounced, but transmission may peak in spring and summer when environmental conditions favor egg development. Zoonotic transmission to humans occurs through accidental ingestion of embryonated eggs, leading to visceral larva migrans (VLM) or ocular larva migrans (OLM), particularly in children with pica. The prevalence of Toxocara antibodies in human populations ranges from 2-14% in developed countries to over 50% in some developing regions.

The pathophysiology of toxocariasis depends on the host's age and immune status. In neonatal puppies and kittens, ingested infective eggs hatch in the small intestine, and L2 larvae penetrate the intestinal wall, entering the portal circulation. They migrate to the liver, then to the lungs via the hepatic veins and caudal vena cava. In the lungs, larvae break into alveoli, ascend the trachea, and are coughed up and swallowed, returning to the small intestine to mature into adults. This tracheal migration causes significant pulmonary hemorrhage and inflammation, leading to respiratory distress in heavily infected neonates. In older animals (typically >6 months), larvae undergo somatic migration, traveling to various tissues (liver, lungs, muscle, brain) where they become encapsulated and enter hypobiosis. These arrested larvae can be reactivated in pregnant females, crossing the placenta to infect fetuses (prenatal infection) or migrating to the mammary glands to be shed in milk (lactogenic infection). The adult worms in the intestine cause mechanical irritation, competition for nutrients, and can lead to intestinal obstruction, intussusception, or perforation in heavy infections. The immune response involves Th2-type reactions with eosinophilia, mast cell activation, and IgE production. Chronic infection can lead to granulomatous inflammation in tissues where larvae are trapped. In paratenic hosts (including humans), larvae do not mature but migrate through tissues, causing VLM (hepatomegaly, eosinophilia, fever) or OLM (retinal granuloma, uveitis). The severity of disease correlates with larval burden and host immune response.

Intrinsic factors include age, with puppies and kittens being highly susceptible due to immature immune systems and the high likelihood of prenatal or lactogenic infection. Young animals (under 6 months) are most likely to develop patent intestinal infections with high egg shedding. Genetic factors may influence susceptibility, but specific breed predispositions are not well-established. Immunosuppression (e.g., from concurrent viral infections, corticosteroid therapy, or malnutrition) can reactivate hypobiotic larvae and increase egg shedding. Extrinsic factors include poor sanitation, overcrowding, and lack of routine deworming programs. Dams are a major source of infection for offspring via transplacental and transmammary routes. Environmental contamination with embryonated eggs is a key risk factor; eggs are extremely resistant and can survive in soil for years. Paratenic hosts (rodents, birds) can serve as a source of infection for cats and dogs that hunt. Dietary factors, such as ingestion of contaminated soil (pica) or raw paratenic hosts, increase exposure. Management practices, such as not removing feces promptly, allowing dogs to roam freely, and not implementing regular fecal examinations, contribute to transmission.

Clinical signs vary with age and infection intensity. In neonatal puppies and kittens (2-4 weeks old), signs are often severe and include respiratory distress (coughing, dyspnea, pneumonia), abdominal distension, poor growth, vomiting, diarrhea, and failure to thrive. Heavy intestinal burdens can cause intestinal obstruction, intussusception, or rupture, leading to acute abdomen and shock. In older puppies and kittens (6 weeks to 6 months), signs are more moderate: pot-bellied appearance, dull hair coat, intermittent diarrhea, vomiting, and mild respiratory signs. Adult dogs and cats are typically asymptomatic, but chronic infections may cause weight loss, poor coat condition, and occasional gastrointestinal signs. In pregnant females, reactivated larvae can cause no clinical signs but lead to infection of offspring. Eosinophilia is a common laboratory finding but is not always present. In paratenic hosts (humans), VLM presents with fever, hepatosplenomegaly, eosinophilia, and pulmonary symptoms; OLM presents with unilateral visual impairment, strabismus, and retinal lesions. Neurological signs (seizures, meningitis) are rare but possible. In cats, infection with Toxocara cati may also cause coughing, vomiting, and diarrhea, but signs are often milder than in dogs.

Differential diagnoses for toxocariasis in young animals include other intestinal parasites such as Ancylostoma spp. (hookworms), which cause anemia and diarrhea; Trichuris vulpis (whipworms) in dogs, causing large bowel diarrhea; Giardia spp., causing malabsorptive diarrhea; and Coccidia (Isospora spp.), causing bloody diarrhea. Viral infections such as canine parvovirus or feline panleukopenia can cause severe gastroenteritis with vomiting and diarrhea, but are often accompanied by leukopenia and fever. Bacterial enteritis (e.g., Salmonella, Campylobacter) may present with acute diarrhea. Respiratory signs in neonates may be confused with aspiration pneumonia, congenital heart disease, or viral pneumonia (e.g., canine distemper, feline herpesvirus). Intestinal obstruction from other causes (foreign bodies, intussusception) should be considered. In adult animals, weight loss and gastrointestinal signs may be due to inflammatory bowel disease, exocrine pancreatic insufficiency, or neoplasia. Eosinophilia can also be seen in other parasitic infections (heartworm, lungworms), hypersensitivity disorders, or eosinophilic gastroenteritis. Definitive diagnosis is based on fecal flotation demonstrating characteristic eggs.

The diagnostic approach begins with a thorough history and physical examination, focusing on age, deworming history, and environmental exposure. In young animals with compatible signs, a fecal flotation test (using zinc sulfate or Sheather's sugar solution) is the first-line diagnostic. Toxocara eggs are readily identified by their thick, pitted shells and size. If eggs are not found but clinical suspicion is high, repeated fecal examinations (3 consecutive days) may be necessary. For neonatal puppies with respiratory signs, a transtracheal wash or bronchoalveolar lavage may reveal larvae, but this is rarely needed. In cases of suspected prenatal infection, fecal examination of puppies at 2-4 weeks of age is recommended. For adult animals with chronic signs, a complete blood count (CBC) may show eosinophilia, but this is nonspecific. Serological tests (ELISA) for Toxocara antibodies are available but are not routinely used in veterinary practice due to cross-reactivity and inability to distinguish past from current infection. In paratenic hosts (humans), diagnosis is based on clinical signs, eosinophilia, and positive serology (ELISA with Western blot confirmation). Imaging (abdominal ultrasound) may reveal intestinal thickening or obstruction in heavy infections. A therapeutic trial with an anthelmintic (e.g., fenbendazole) can be both diagnostic and therapeutic if clinical improvement occurs. The diagnostic algorithm should also include screening for other parasites and pathogens, especially in cases of diarrhea or respiratory distress.

Hematology: Complete blood count often reveals eosinophilia, particularly during larval migration. In heavy infections, anemia may be present due to blood loss from intestinal ulceration or concurrent hookworm infection. Leukocytosis with neutrophilia may occur secondary to inflammation or bacterial infection. Serum biochemistry: Generally unremarkable, but in cases of hepatic larval migration, mild elevations in liver enzymes (ALT, AST) may be seen. Hypoalbuminemia can occur in severe enteritis due to protein-losing enteropathy. Urinalysis: Typically normal. Blood gas analysis: May show hypoxemia in neonates with severe pulmonary involvement. Specific biomarkers: Eosinophil count is the most useful marker; elevated IgE levels may be seen. Serology: ELISA for Toxocara antibodies is used in research and for human diagnosis; in animals, it is not routinely performed. PCR: Fecal PCR for Toxocara spp. is available and can differentiate species, but is not widely used. Fecal flotation: The gold standard for diagnosis, demonstrating characteristic eggs (75-90 μm, thick shell, pitted surface). In neonatal infections, eggs may be present as early as 2-3 weeks after birth. Fecal antigen tests (e.g., coproantigen ELISA) are also available and may be more sensitive than flotation in some cases.

Radiography: Thoracic radiographs in neonates with pulmonary migration may show a diffuse interstitial or bronchial pattern, sometimes with alveolar infiltrates in severe cases. Abdominal radiographs may reveal a distended bowel loop or signs of obstruction (e.g., foreign body, intussusception) in heavy infections. Ultrasonography: Abdominal ultrasound can show thickened intestinal walls, increased echogenicity of the intestinal mucosa, and sometimes the presence of adult worms as linear hyperechoic structures within the intestinal lumen. In cases of obstruction, ultrasound may reveal intussusception or a mass effect. Echocardiography: Not directly relevant, but if heartworm disease is a differential, it may be performed. Computed Tomography (CT): Not routinely used for toxocariasis, but may be helpful in cases of suspected visceral larva migrans in paratenic hosts, showing hepatosplenomegaly or granulomatous lesions. Magnetic Resonance Imaging (MRI): In human ocular larva migrans, MRI of the orbit can reveal a retinal granuloma. Endoscopy: Upper gastrointestinal endoscopy may occasionally visualize adult worms in the duodenum, but is not a primary diagnostic tool. Fluoroscopy: Not used. Overall, imaging is most valuable for assessing complications such as obstruction or pneumonia.

Cytology: Fine needle aspirate of enlarged lymph nodes or liver may show eosinophilic inflammation, but is rarely diagnostic. Bronchoalveolar lavage fluid in neonates with pulmonary migration may contain larvae, eosinophils, and macrophages. Histopathology: Intestinal biopsy (if performed) may show adult worms in the lumen, with villous atrophy, crypt hyperplasia, and eosinophilic infiltration of the lamina propria. In cases of larval migrans, granulomatous inflammation with central necrosis and eosinophilic infiltrates may be seen in the liver, lungs, or other tissues. The larvae themselves may be identified in tissue sections, but are often degenerate. Special stains (e.g., Giemsa, periodic acid-Schiff) can help highlight larval structures. In paratenic hosts, biopsy of affected organs (e.g., liver) may show granulomas containing larvae. However, histopathology is rarely needed for diagnosis, as fecal flotation is usually sufficient.

Treatment of toxocariasis involves anthelmintic therapy, supportive care, and environmental control. The drug of choice for dogs and cats is fenbendazole (50 mg/kg PO q24h for 3 consecutive days) or pyrantel pamoate (5-10 mg/kg PO, repeated at 2-week intervals). For puppies, treatment should begin at 2 weeks of age and be repeated every 2 weeks until 8 weeks of age, then monthly until 6 months of age. For kittens, treatment should begin at 3 weeks of age and follow a similar schedule. Milbemycin oxime (0.5-1.0 mg/kg PO monthly) and moxidectin (2.5-6.0 μg/kg PO monthly) are effective for prevention and treatment. Selamectin (6-12 mg/kg topical monthly) is also effective. In cases of heavy infection with respiratory distress, supportive care includes oxygen therapy, bronchodilators (e.g., terbutaline 0.01 mg/kg SC or IV q4-6h), and anti-inflammatory doses of corticosteroids (e.g., prednisone 0.5-1.0 mg/kg PO q12h) to reduce inflammation. Fluid therapy is indicated for dehydrated or anorexic animals. For intestinal obstruction, surgical intervention may be necessary. In pregnant bitches, fenbendazole (50 mg/kg PO q24h) from day 40 of gestation to day 14 postpartum can reduce prenatal and lactogenic transmission. Environmental decontamination is crucial: remove feces daily, clean surfaces with hot water and detergent, and use bleach or boiling water to kill eggs (though eggs are resistant). In human cases of VLM or OLM, treatment includes albendazole (400 mg PO q12h for 5 days) or mebendazole (100-200 mg PO q12h for 5 days), often with corticosteroids for severe inflammation.

The prognosis for toxocariasis is generally excellent with appropriate treatment. Puppies and kittens with uncomplicated infections respond well to anthelmintic therapy, with clinical signs resolving within days. However, severe neonatal infections with pulmonary involvement can be fatal if not treated promptly; mortality rates can be high in untreated cases. Chronic infections in adult animals are usually subclinical and have a good prognosis. Complications such as intestinal obstruction or intussusception require surgical intervention and carry a guarded prognosis depending on the extent of damage. In paratenic hosts (humans), VLM is usually self-limiting but can be severe in heavy infections; OLM can cause permanent visual impairment. Negative prognostic indicators include severe respiratory distress, failure to respond to anthelmintics, and concurrent infections. Reinfection is possible if environmental contamination is not addressed, so long-term control measures are essential. Overall, with proper deworming protocols and hygiene, the prognosis is favorable.

Follow-up care for toxocariasis includes repeated fecal examinations to confirm clearance of infection. For puppies and kittens, fecal exams should be performed at each deworming visit (every 2 weeks until 8 weeks of age, then monthly until 6 months). After treatment, a fecal exam should be repeated 2-4 weeks later to ensure no eggs are present. For adult animals, annual fecal exams are recommended, and monthly heartworm preventives that include anthelmintic activity (e.g., milbemycin, moxidectin) should be continued. In breeding facilities, a strict deworming protocol for dams and offspring is essential. Environmental management includes regular removal of feces, cleaning of kennels with high-pressure water and disinfectants, and preventing access to contaminated soil. For human cases, follow-up is based on clinical resolution and serological monitoring. In animals with severe respiratory signs, thoracic radiographs should be repeated to document resolution. Long-term management includes maintaining good hygiene and preventing predation on paratenic hosts. Client education is crucial to emphasize the zoonotic risk and the importance of deworming.

Pearls: 1. Always consider toxocariasis in any puppy or kitten with failure to thrive, respiratory distress, or a pot-bellied appearance. 2. Fecal flotation is highly sensitive; a single negative test does not rule out infection, especially in early infections. 3. In neonatal puppies, respiratory signs may be the first indication of prenatal infection; initiate treatment immediately. 4. Use fenbendazole in pregnant bitches to reduce transplacental transmission. 5. Monthly heartworm preventives with anthelmintic activity are effective for control. 6. Educate clients about zoonotic risk, especially for children. Pitfalls: 1. Do not use piperazine alone, as it is less effective and has a narrow spectrum. 2. Avoid using ivermectin in puppies under 6 weeks of age or in breeds sensitive to ivermectin (e.g., Collies). 3. Do not forget to treat the environment; reinfection is common if eggs remain. 4. Do not overlook concurrent infections (e.g., hookworms, coccidia) that may require additional treatment. 5. In cases of intestinal obstruction, do not delay surgery; anthelmintics alone will not resolve the obstruction. 6. Do not rely solely on clinical signs; confirm with fecal examination.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1. Fenbendazole (Panacur): 50 mg/kg PO q24h for 3 days. Safe for puppies and kittens over 2 weeks of age. For pregnant bitches, administer from day 40 of gestation to day 14 postpartum. 2. Pyrantel pamoate (Strongid): 5-10 mg/kg PO, repeated at 2-week intervals. Safe for puppies and kittens over 2 weeks of age. 3. Milbemycin oxime (Interceptor): 0.5-1.0 mg/kg PO monthly. Safe for puppies and kittens over 2 weeks of age. 4. Moxidectin (ProHeart, Advantage Multi): 2.5-6.0 μg/kg PO monthly (ProHeart) or topical (Advantage Multi) at 10 mg/kg. Safe for puppies and kittens over 7 weeks of age. 5. Selamectin (Revolution): 6-12 mg/kg topical monthly. Safe for puppies and kittens over 6 weeks of age. 6. Piperazine: 100-200 mg/kg PO, but less effective and not recommended as first-line. 7. For severe respiratory signs, consider prednisone: 0.5-1.0 mg/kg PO q12h for 3-5 days, tapering. 8. For human VLM/OLM: Albendazole 400 mg PO q12h for 5 days; Mebendazole 100-200 mg PO q12h for 5 days. Always adjust dosages for renal or hepatic impairment; most anthelmintics are safe, but caution with ivermectin in sensitive breeds. Drug interactions are minimal, but avoid concurrent use of piperazine with other anthelmintics.

Key studies and consensus guidelines: 1. The Companion Animal Parasite Council (CAPC) recommends deworming puppies every 2 weeks from 2 to 8 weeks of age, then monthly to 6 months, and then quarterly to annually. 2. A study by Overgaauw et al. (2009) demonstrated that transplacental transmission is the primary route in dogs, and fenbendazole treatment of pregnant bitches significantly reduces neonatal infection. 3. A meta-analysis by Lee et al. (2010) found that the prevalence of Toxocara in dogs is higher in stray and shelter populations, emphasizing the need for public health interventions. 4. The European Scientific Counsel Companion Animal Parasites (ESCCAP) guidelines recommend monthly anthelmintic treatment in areas with high risk. 5. A study by Fisher (2003) reviewed the efficacy of various anthelmintics, showing that fenbendazole and pyrantel are highly effective against adult worms, while milbemycin and moxidectin have larvicidal activity. 6. In human toxocariasis, a randomized controlled trial by Delgado et al. (1989) showed that albendazole is more effective than mebendazole for VLM. 7. The ACVIM consensus statement on zoonotic parasites (2015) emphasizes the importance of routine deworming and client education. 8. A study by Despommier (2003) reviewed the pathophysiology of larva migrans, highlighting the role of eosinophils and granuloma formation. These evidence-based recommendations support the use of strategic deworming protocols and environmental control to reduce the burden of toxocariasis in animals and humans.